10-Q: Geron Reports Q2 2025 Results, RYTELO Sales Rise

Geron Corporation reported a net loss of $16.4 million in Q2 2025, with RYTELO product revenue reaching $49.0 million, as the company continues its commercialization efforts and advances clinical trials.

Summary

• Geron Corporation reported a net loss of $16.4 million for the three months ended June 30, 2025, a significant improvement from a $67.4 million net loss in the same period of 2024.
• Product revenue from RYTELO, which began shipping in June 2024, was $49.0 million for Q2 2025 and $88.4 million for the six months ended June 30, 2025.
• Total revenues for Q2 2025 were $49.0 million, up from $0.9 million in Q2 2024.
• Research and development expenses decreased by 29% to $21.7 million in Q2 2025 compared to $30.8 million in Q2 2024, primarily due to decreased activity in the Phase 3 IMerge MDS study post-FDA approval and capitalization of manufacturing costs.
• Selling, general and administrative expenses decreased slightly to $38.6 million in Q2 2025 from $39.4 million in Q2 2024, but increased to $78.6 million for the six months ended June 30, 2025, from $66.5 million in the prior year period, driven by increased headcount for RYTELO commercialization.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $432.6 million as of June 30, 2025, down from $502.9 million at December 31, 2024.
• The company's accumulated deficit reached approximately $1.8 billion as of June 30, 2025.
• Geron expects total gross-to-net adjustments for RYTELO to be in the midto high-teens percentage of gross product revenue for the remaining quarters of 2025.
• The Phase 3 IMpactMF clinical trial for myelofibrosis has reached over 95% enrollment and is expected to complete enrollment by the end of 2025.
• The company received marketing authorization for RYTELO in the European Union in March 2025 and is preparing for commercialization in select EU markets in 2026, planning to work with third parties for this.
• Two securities class action lawsuits and three shareholder derivative complaints have been consolidated, alleging false and misleading statements regarding RYTELO's commercial potential.
• The company has noncancelable commercial purchase commitments for approximately $124.7 million related to RYTELO manufacturing as of June 30, 2025.

Sentiment

Score: 4

Explanation: While RYTELO's initial commercial launch shows promising revenue growth year-over-year and the EU approval is a positive step, the company continues to incur substantial net losses and faces significant legal challenges. The variability in sequential quarterly sales, coupled with the explicit acknowledgment of unproven commercial potential and the need for potential future capital raises, indicates a high degree of uncertainty and financial risk. The long-term success of RYTELO and the company's path to profitability remain highly speculative.

Positives

• RYTELO product revenue significantly increased to $49.0 million in Q2 2025 from $0.8 million in Q2 2024, demonstrating initial commercial traction.
• Net loss substantially narrowed to $16.4 million in Q2 2025 from $67.4 million in Q2 2024, indicating improved financial performance year-over-year.
• European Commission granted marketing authorization for RYTELO in March 2025, opening new market opportunities for the product.
• The Phase 3 IMpactMF clinical trial has achieved over 95% enrollment and is expected to complete enrollment by the end of 2025, progressing towards key milestones.
• The company maintains a solid cash position with $432.6 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2025.
• Cost of goods sold remains low as a percentage of net product revenue due to previously expensed inventory prior to FDA approval, positively impacting gross margins for the next 12-15 months.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of approximately $1.8 billion as of June 30, 2025.
• RYTELO sales trends have shown variability, with Q2 2025 net product revenue ($49.0 million) being higher than Q1 2025 ($39.4 million) but lower than Q4 2024 ($47.5 million), indicating inconsistent growth.
• Interest expense significantly increased to $8.5 million in Q2 2025 from $3.3 million in Q2 2024, primarily due to the Pharmakon Loan Agreement and Royalty Pharma Agreement.
• The company is subject to ongoing securities class action and shareholder derivative lawsuits alleging false and misleading statements about RYTELO's commercial potential, which could result in substantial damages and divert management attention.
• Reliance on a small group of third-party manufacturers and a single source for API for RYTELO poses supply chain risks, as evidenced by a recent FDA inspection identifying deficiencies at one manufacturer.
• The company has limited experience as a commercial company outside the U.S. and plans to rely on third parties for EU commercialization, which may not be successful or on favorable terms.
• Future funding requirements are substantial and depend on RYTELO sales, with no assurance that additional capital will be available on acceptable terms, if at all, potentially leading to dilution for stockholders.

Risks

• Near-term prospects are wholly dependent on RYTELO, and failure to successfully commercialize it in the U.S. or expand its indications would materially and adversely affect revenue and profitability.
• Limited experience as a commercial company means sales, marketing, and distribution of RYTELO may be unsuccessful or less successful than anticipated.
• Inability to maintain acceptable prices or adequate reimbursement for RYTELO could severely limit its use.
• RYTELO must be accepted by the healthcare community, which can be slow to adopt new technologies, potentially limiting market penetration.
• Competitors developing superior or more cost-effective products could significantly impact RYTELO's commercial viability.
• Reliance on a select network of third-party distributors and specialty pharmacies for U.S. distribution, and any failure by them, could adversely affect revenues.
• Subject to pricing, drug marketing, post-market, and reimbursement regulations in the EU, which may materially affect commercialization and reimbursement.
• Inability to maintain regulatory approvals for RYTELO in the U.S. and EU for lower-risk MDS could severely affect business.
• Regulatory approval for RYTELO is subject to post-marketing requirements and commitments, with potential penalties or product withdrawal for non-compliance.
• Inability to obtain regulatory approval for RYTELO in other jurisdictions or for new indications, or significant delays, could severely affect business.
• RYTELO may cause undesirable or unintended side effects or adverse events, which could halt or limit commercialization, delay regulatory approval, or terminate clinical trials.
• Results from prior non-clinical studies and clinical trials may not predict success in later clinical trials, including IMpactMF.
• Failure to maintain a manufacturing supply chain to adequately supply RYTELO for commercial and future clinical uses would adversely affect commercialization and clinical trials.
• If third parties manufacturing RYTELO fail to perform, commercial and clinical supply could be interrupted or limited.
• History of net losses and may not achieve consistent future profitability for some time, if ever.
• Operating results are unpredictable and may fluctuate; if below expectations, stock price could decline.
• Failure to obtain additional capital, if and when needed, would force delays, reductions, or elimination of RYTELO development or commercialization.
• Inability to obtain and maintain sufficient intellectual property protection and relevant regulatory exclusivities for RYTELO could allow competitors to commercialize similar products.
• Involvement in lawsuits to protect or enforce patents or other intellectual property rights could be expensive, time-consuming, and unsuccessful.
• Subject to infringement claims that are costly to defend and may limit ability to use disputed technologies.
• Inability to successfully retain or recruit key personnel to support commercialization and development, or to otherwise successfully manage growth.
• Management transition creates uncertainties and could harm business.
• Inability to establish potential future collaborative arrangements for RYTELO on acceptable terms, or at all, may delay or abandon commercialization or further development.
• Subject to U.S. and foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws, with compliance potentially impairing ability to compete.
• If information technology systems or data, or those of third parties, are compromised, could experience adverse consequences including regulatory actions, litigation, and business disruption.
• Subject to stringent and changing U.S. and foreign laws, regulations, and obligations related to data privacy and security, with non-compliance leading to significant consequences.
• Historically, stock price has been extremely volatile, and investment may suffer a decline in value.
• Failure to maintain compliance with Nasdaq listing requirements could result in delisting.
• Provisions in charter, bylaws, and Delaware law may inhibit potential acquisition bids.
• Do not intend to pay cash dividends on common stock in the foreseeable future.
• Employees, independent contractors, or vendors may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Business could be negatively impacted by environmental, social, and corporate governance (ESG) matters or reporting of such matters.
• Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect.
• Changes in tax laws or regulations that are applied adversely could have a material adverse effect.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.

Future Outlook

Geron expects operating expenses for 2025 to be in the range of approximately $270 million to $285 million, driven by continued investment in RYTELO commercialization, commercial supply redundancy, post-marketing commitments, and initial preparations for the EU launch in 2026. Interest expense is also anticipated to increase due to the Pharmakon Loan Agreement and Royalty Pharma Agreement. The company believes its existing cash and anticipated RYTELO revenues will fund projected operating requirements for the foreseeable future, but acknowledges potential needs for additional funding if sales do not meet expectations or unforeseen events occur.

Management Comments

• Our priority is to drive new patient starts across the breadth of the eligible patient population in RYTELO's approved indication in the U.S.
• Our strategy to drive sales growth in the U.S. is currently focused on three key areas: investing additional resources to increase brand awareness, including increasing the size of our commercial and medical field forces; refining our marketing and medical efforts to enhance prescribing clarity and confidence with the approved use of RYTELO; and implementing programs to expand key opinion leader support and advocacy.
• We are preparing for the planned commercialization of RYTELO in select EU markets in 2026.
• At this time, we do not plan to commercialize RYTELO independently in the EU (or in any other regions outside of the United States where RYTELO may be approved for marketing in the future). Accordingly, we plan to work with experienced third parties for the commercialization and marketing of RYTELO in the EU.
• The Phase 3 IMpactMF clinical trial has reached over 95% enrollment and we expect to complete enrollment by the end of 2025.
• Based on our current planning assumptions for enrollment and event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028.

Industry Context

Geron operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically targeting hematologic malignancies. The company's first-in-class telomerase inhibitor, RYTELO, aims to address high unmet needs in lower-risk Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF). The industry faces increasing scrutiny over drug pricing and reimbursement, as well as challenges in supply chain management and intellectual property protection. Geron's strategy of focusing on a single approved product (RYTELO) and seeking third-party partnerships for international commercialization is a common approach for smaller biopharmaceutical companies entering the commercial stage, but it also concentrates risk.

Comparison to Industry Standards

• NA The filing does not provide specific comparable company, project, or result data for direct assessment against global benchmarks. The company acknowledges competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, but does not detail specific comparative performance metrics.

Management Changes

Corporate Governance

Legal Proceedings

• Two putative securities class action lawsuits (Dabestani v. Geron Corporation, et al. and Potvin v. Geron Corporation, et al.) were filed and consolidated into In re Geron Corporation Securities Litigation. These lawsuits allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, claiming the company overstated RYTELO's commercial potential.
• Three purported stockholder derivative complaints (Bishop v. Scarlett, et al., Lerner v. Scarlett, et al., and Willis v. Scarlett, et al.) were filed and consolidated into In re Geron Corporation Derivative Litigation. These lawsuits name current and former directors and officers, alleging breach of fiduciary duties and federal securities law violations based on similar claims as the securities class actions.
• The Consolidated Derivative Action has been stayed pending a final ruling on the anticipated motion to dismiss in the Securities Class Action.
• The company intends to vigorously defend against these claims, acknowledging that such lawsuits are subject to inherent uncertainties, significant resource expenditure, and potential substantial legal fees and costs.

Related Party Transactions

• The filing does not disclose any specific related party transactions beyond standard compensation and equity plans for employees and directors, and the Royalty Pharma Agreement which is accounted for as a financing liability.

Stakeholder Impact

• **Shareholders:** Face potential dilution from future equity raises (e.g., At Market Issuance Sales Agreement, increased equity plan shares) and stock price volatility due to unpredictable operating results and ongoing legal proceedings. The accumulated deficit and continued net losses indicate that profitability is not yet achieved, impacting shareholder value.
• **Employees:** Benefit from stock-based compensation plans and employee stock purchase plans. Management changes (new CEO, EVPs) could impact organizational structure and culture. The company's ability to retain and recruit key personnel is crucial for commercialization and development.
• **Customers (Healthcare Providers & Patients):** RYTELO's commercial success depends on market acceptance, pricing, and reimbursement. Safety and efficacy data from ongoing trials and post-marketing surveillance will continue to influence prescribing decisions and patient access. Legal proceedings could impact company reputation and trust.
• **Suppliers/Manufacturers:** The company relies heavily on third-party manufacturers for RYTELO, creating interdependence. Any failures or deficiencies at these manufacturers could disrupt supply, impacting the company's ability to meet demand and conduct trials.
• **Creditors:** The company has significant debt obligations under the Pharmakon Loan Agreement and a liability related to the sale of future royalties. Its ability to service this debt depends on RYTELO's commercial success and future capital raises.

Next Steps

• Complete enrollment for the Phase 3 IMpactMF clinical trial by the end of 2025.
• Prepare for planned commercialization of RYTELO in select EU markets in 2026, working with experienced third parties.
• Conduct interim analysis for Overall Survival (OS) in the IMpactMF trial in the second half of 2026.
• Conduct final analysis for Overall Survival (OS) in the IMpactMF trial in the second half of 2028.
• Continue to support the commercialization of RYTELO in the U.S. by investing additional resources to increase brand awareness, refining marketing efforts, and expanding key opinion leader support.
• Continue development of imetelstat for other myeloid hematologic malignancies, including the Phase 1 IMproveMF combination clinical trial in frontline MF and the Phase 2 investigator-led IMpress clinical trial in higher-risk MDS and acute myeloid leukemia.
• Fulfill post-marketing requirements and commitments for RYTELO in the U.S. and EU, including assessing long-term safety in the IMerge trial and evaluating alternative dosing regimens.

Key Dates

Recommendation

Geron Corporation is at a pivotal stage with its first commercial product, RYTELO, showing initial revenue generation and securing EU marketing authorization. This provides a foundation for future growth. However, the company continues to operate at a significant net loss, has a substantial accumulated deficit, and faces ongoing legal challenges that could result in considerable financial and reputational costs. The variability in RYTELO's sequential sales and the explicit acknowledgment of unproven commercial potential introduce uncertainty. While the long-term potential of RYTELO in addressing unmet medical needs is present, the financial risks, including the need for potential future capital raises and reliance on third-party manufacturing, warrant a cautious approach. A 'hold' recommendation reflects the balance between the promising commercial launch and pipeline progress against the significant financial and operational hurdles that still need to be overcome before a clear path to sustained profitability is established.

Keywords

Geron Corporation, RYTELO, Imetelstat, Myelodysplastic Syndromes, MDS, Myelofibrosis, MF, Hematologic Malignancies, Biopharmaceutical, Oncology, SEC Filing, 10-Q, Clinical Trials, FDA Approval, Commercialization, Drug Development, Telomerase Inhibitor, Orphan Drug, Financial Results, Biotech, Pharmaceutical